Managed care expects to broaden Crestor use

More good news for AstraZeneca's Crestor: Managed care pharmacy directors are saying they'll pay for the statin for healthy patients without high LDL cholesterol, but with elevated high sensitivity C-reactive protein, after the Jupiter trial found outcomes benefits from Crestor use in those patients. Release

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.